– Summing up – it has been a good year for #NanoGroup S.A. We have even more ambitious goals and plans for the future – says Przemysław Mazurek, CEO of #NanoGroup S.A., highlighting the achievements of the past year, 2025.
First and foremost, the #NanOX System is in an advanced stage of development. Its effectiveness was confirmed in July 2024 during a successful experiment involving the autotransplantation of a pig kidney.
The experiment, conducted by a team led by prof. dr. hab. Maciej Kosieradzki from the Medical University of Warsaw (WUM), involved extracting one kidney from an animal after a 30-minute cardiac arrest. The kidney was then perfused with the #NanOX solution using the NanOX Recovery Box under ex vivo subnormothermic conditions, specifically at 25°C, for 12 hours. In the next stage, after removing the animal’s second kidney, researchers transplanted the organ that had undergone ex vivo perfusion. Over the following two weeks, the animal’s health and the function of the transplanted kidney were closely monitored. By the eighth day post-surgery, the animal regained full functionality, and the transplanted kidney performed excellently, as confirmed by biochemical tests.
This experiment, along with earlier ones, validated the efficacy of the solution, which not only allows for significantly prolonged ex vivo organ storage but also facilitates regeneration. In the future, it may enable treatments such as organ rejuvenation or fat removal.
– We have scientific confirmation that we are on the right track to significantly improving organ viability and their further usability for transplantation compared to fluids currently available on the market. I am pleased to announce the start of the next research phase, whose anticipated positive results will mark another key step toward bringing our technology to market – summarized Piotr Mierzejewski, Vice President of the Management Board of #NanoGroup S.A.
In September, #NanoGroup S.A. submitted a funding application under the Medical Research Agency program and has now advanced to the substantive evaluation phase in the ABM competition.
#NanoGroup S.A. also applied for funding under the European Funds (FENG) program. The company intends to use the acquired funds to accelerate the development of innovative projects, such as the #NanOX organ perfusion system and new cancer therapies.
#NanoGroup S.A. has also filed two patent applications:
The #NanOX perfusion fluid – an innovative solution supporting the perfusion of organs designated for transplantation, enabling oxygenation, nourishment, and regeneration.
A blood substitute – a groundbreaking fluid based on PFC nanoemulsion, capable of oxygenating the body without the use of human blood.
Additionally, the CEO of #NanoGroup S.A. outlined plans for 2025, aligned with the updated NanoGroup strategy for 2023–2025:
– By the end of next year, we aim to have at least five projects in our portfolio. We are planning changes to our approach to project implementation, particularly significantly shortening the time required to reach the commercialization stage. These are the main goals of NanoGroup’s new strategy for 2023–2025. The company intends to complete the preclinical research phase by the end of next year and begin clinical trials in 2026, which will continue over the following years. NanoGroup anticipates starting the certification process in 2029. These are ambitious plans, but they are entirely achievable – announced Przemysław Mazurek.